Combining Enzalutamide with Radium-223 Significantly Improves rPFS as First-Line Therapy for Patients with mCRPC By Ogkologos - August 27, 2025 347 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the PEACE-3 study Source RELATED ARTICLESMORE FROM AUTHOR Significant PFS Improvement with Ibrutinib-Rituximab Compared to Immunochemotherapy in Previously Untreated Patients with Mantle Cell Lymphoma EMA Recommends a Change to the Terms of the Marketing Authorisation for Mosunetuzumab Combining Niraparib with Abiraterone Acetate and Prednisone Significantly Improves rPFS in Patients with mCSPC Harbouring BRCA1/2 or Other HRR Gene Alterations MOST POPULAR Adjuvant Pembrolizumab Improves Overall Survival Among Patients with Clear-Cell Renal Cell... April 24, 2024 TG4001 Therapeutic Vaccination Plus Avelumab-Mediated PD-L1 Blockade Improves Tumour Microenvironment in... December 12, 2020 Study Identifies a Potential Cause of Immunotherapy’s Heart-Related Side Effects December 22, 2022 Dogs Can Sniff Out COVID-19 After Just One Week Of Training,... July 28, 2020 Load more HOT NEWS Preparing for the End of the U.S. Public Health Emergency (PHE):... Single Mom Has To Beg For Rides To Doctor For Son... Large DFS Benefit from Adjuvant Cemiplimab Among Patients at High Risk... Intratumoural and Intracavitary Administration of Ipilimumab Plus Nivolumab Is Feasible and...
